1. Safety and Tolerability of Tegaserod in Patients With Chronic Constipation: Pooled Data From Two Phase III Studies 
Eamonn M.M. Quigley, Arnold Wald, James Fidelholtz, Michel Boivin, Eckhard Pecher, David Earnest 
Clinical Gastroenterology and Hepatology 
Volume 4, Issue 5, Pages (May 2006)
DOI: /j.cgh
Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

2. Figure 1
Summary of the 2 phase III trial study designs. (Patients were recruited from 105 centers in North and South America and 128 centers in Europe, South Africa, and Australia.) b.i.d., twice a day.
Clinical Gastroenterology and Hepatology 2006 4, DOI: ( /j.cgh )
Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

3. Figure 2 Summary of patient flow. b.i.d., twice a day.
Clinical Gastroenterology and Hepatology 2006 4, DOI: ( /j.cgh )
Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

4. Figure 3
Frequency of AEs leading to discontinuation (>1 patient on tegaserod). b.i.d., twice a day; NOS, not otherwise specified.
Clinical Gastroenterology and Hepatology 2006 4, DOI: ( /j.cgh )
Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions